Global vital organ therapy company Vantive is stepping up its commitment to advancing life-saving treatments for critically ill patients. The company unveiled new clinical evidence supporting Extracorporeal Blood Purification (EBP)—an innovative therapy for sepsis and organ failure—at the 6th Asia Pacific Acute Kidney Injury & Continuous Renal Replacement Therapy (APAC AKI CRRT) Conference 2025 in Bangkok, Thailand.
“By partnering with Vantive, we’re turning research into real-world solutions that save lives across Asia,” said Professor Nattachai Srisawat, MD, PhD, lead author of the consensus from Thailand. “This collaboration helps clinicians act faster and more effectively in treating organ failure.”
Professor Pham Chi Ngoc Thao of Cho Ray Hospital, Vietnam, added: “In critical care, every minute counts. Vantive’s innovations empower us to manage complex cases with more confidence and precision.”
Held from 2nd–4th October 2025, the APAC AKI CRRT Conference gathered medical experts from across the region to discuss the latest in kidney and multi-organ support. Vantive’s participation underscores its long-standing mission to extend lives and expand possibilities through innovation, education, and collaboration.
“We’re proud to work alongside the clinical community to advance therapies that make a real difference for ICU patients,” said Dr. Kuljinder Singh, APAC Medical Director at Vantive. “Our focus is on driving new approaches in sepsis management and supporting hospitals in Malaysia and beyond.”
